Furthermore, we demonstrated that LSD1 promoted tumor heterogeneity and lineage plasticity in BRAFV600E CRC and that targeting LSD1 by epigenetic therapy improved responses to BRAFi plus EGFRi by blocking therapy-induced lineage plasticity. Here, KDM1A is linked to neoplasm.